We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+11.92%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$191M
AUM Growth
-$59.3M
(-24%)
Cap. Flow
-$76.2M
Cap. Flow
% of AUM
-39.78%
Top 10 Holdings %
Top 10 Hldgs %
5.8%
Holding
489
New
53
Increased
164
Reduced
226
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
D.R. Horton
DHI
|
+$888K |
| 2 |
Lennar Class A
LEN
|
+$880K |
| 3 |
Microchip Technology
MCHP
|
+$860K |
| 4 |
Ametek
AME
|
+$859K |
| 5 |
Home Depot
HD
|
+$853K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Steel Dynamics
STLD
|
+$1.62M |
| 2 |
Cheniere Energy
CQP
|
+$1.53M |
| 3 |
STOR
STORE Capital Corporation
STOR
|
+$1.44M |
| 4 |
NOA
North American Construction
NOA
|
+$1.43M |
| 5 |
STR
Sitio Royalties
STR
|
+$1.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.88% |
| 2 | Financials | 12.6% |
| 3 | Technology | 10.15% |
| 4 | Materials | 9.55% |
| 5 | Real Estate | 8.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALLK
326
DELISTED
Allakos
ALLK
| $168K | 0.09% |
+19,981
| New | +$139K |
|
327
Immunovant
IMVT
$7.93B
| $165K | 0.09% |
9,276
-21,091
| -69% | -$266K |
|
|
CERE
328
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $164K | 0.09% |
5,211
+916
| +21% | +$25.8K |
|
329
Runway Growth Finance
RWAY
$237M
| $164K | 0.09% |
14,165
+2,346
| +20% | +$28.2K |
|
330
Design Therapeutics
DSGN
$746M
| $162K | 0.08% |
15,774
+7,999
| +103% | +$108K |
|
331
BioXcel Therapeutics
BTAI
$25.2M
| $158K | 0.08% |
458
-252
| -35% | -$60.9K |
|
332
Crinetics Pharmaceuticals
CRNX
$8.88B
| $157K | 0.08% |
8,598
+2,370
| +38% | +$41.8K |
|
|
MRUS
333
DELISTED
Merus
MRUS
| $156K | 0.08% |
10,106
+4,886
| +94% | +$86K |
|
|
SWTX
334
DELISTED
SpringWorks Therapeutics
SWTX
| $155K | 0.08% |
5,978
+827
| +16% | +$20.4K |
|
335
Protagonist Therapeutics
PTGX
$8.72B
| $155K | 0.08% |
14,235
-2
| -0% | -$17 |
|
336
Celldex Therapeutics
CLDX
$2.81B
| $155K | 0.08% |
3,480
-1,367
| -28% | -$48.8K |
|
337
Cytokinetics
CYTK
$10.8B
| $155K | 0.08% |
3,383
+718
| +27% | +$30.9K |
|
338
Edgewise Therapeutics
EWTX
$4.29B
| $155K | 0.08% |
17,314
-155
| -0.9% | -$1.45K |
|
339
Stoke Therapeutics
STOK
$1.82B
| $154K | 0.08% |
16,715
+6,745
| +68% | +$70.1K |
|
340
Atea Pharmaceuticals
AVIR
$366M
| $153K | 0.08% |
31,762
+16,102
| +103% | +$81.5K |
|
|
NBP
341
NovaBridge Biosciences American Depositary Shares
NBP
$191M
| $152K | 0.08% |
36,476
+24,945
| +216% | +$94.4K |
|
|
RETA
342
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $151K | 0.08% |
3,975
+371
| +10% | +$12.8K |
|
|
RAPT
343
DELISTED
RAPT Therapeutics
RAPT
| $151K | 0.08% |
953
+76
| +9% | +$12.2K |
|
|
PNT
344
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $150K | 0.08% |
20,629
+5,494
| +36% | +$40.8K |
|
345
IDEAYA Biosciences
IDYA
$3.43B
| $150K | 0.08% |
8,259
-897
| -10% | -$15.1K |
|
346
Nuvation Bio
NUVB
$2.3B
| $149K | 0.08% |
77,816
+47,366
| +156% | +$95.8K |
|
|
KYNB
347
Kyntra Bio
KYNB
$28.2M
| $149K | 0.08% |
372
-94
| -20% | -$36K |
|
348
AnaptysBio
ANAB
$1.51B
| $148K | 0.08% |
4,774
-253
| -5% | -$7.14K |
|
|
AFMD
349
DELISTED
Affimed
AFMD
| $147K | 0.08% |
11,870
+7,269
| +158% | +$128K |
|
|
KDNY
350
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $147K | 0.08% |
5,610
-880
| -14% | -$19.5K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q4 2022 Portfolio in Review
As of Q4 2022, Virtus ETF Advisers held 489 positions worth $191M, down 24% from $251M the previous quarter. Its ten largest holdings account for 5.8% of the portfolio.
Virtus ETF Advisers withdrew a net $76.2M in Q4 2022, closing 46 positions and reducing 226 holdings. Its most notable exit was iShares JPMorgan USD Emerging Markets Bond ETF, an estimated $877K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 19% a quarter earlier, followed by Financials and Technology.
Against the trend, Virtus ETF Advisers opened a new position in D.R. Horton worth $987K.
- Virtus ETF Advisers's largest Q4 2022 buy was D.R. Horton: 11,078 shares worth $987K.
- Virtus ETF Advisers added most to Qualcomm in Q4 2022, an estimated $271K increase.
- Virtus ETF Advisers's biggest Q4 2022 reduction was Steel Dynamics, cutting an estimated $1.62M.
- Virtus ETF Advisers fully exited iShares JPMorgan USD Emerging Markets Bond ETF in Q4 2022, selling an estimated $877K.
- Virtus ETF Advisers's ten largest holdings make up 5.8% of its $191M portfolio in Q4 2022.
- Virtus ETF Advisers opened 53 new positions and closed 46 in Q4 2022.
- Virtus ETF Advisers's portfolio value fell 24% quarter-over-quarter to $191M.
Based on Virtus ETF Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.